top of page

BIO 2026: HAYA Therapeutics is focused on how the non-coding "regulatory" portion of the genome causes disease. Its first program targeting cardiac fibrosis is now in the clinic in healthy volunteers

  • 6 hours ago
  • 1 min read

HAYA Co-Founder & CEO Samir Ounzain discusses the WISPER target that came out of the company's work of cataloging long non-coding RNAs, and the role that downregulating it might play in stopping the progression of nonobstructive hypertrophic cardiomyopathy. Plus, other programs, and where an understanding of the regulatory portion of the genome could ultimately take us.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page